Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcturus Therapeutics ( (ARCT) ) has issued an announcement.
On September 26, 2025, Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings Co., Ltd., launched KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine in Japan. This vaccine targets the SARS-CoV-2 Omicron sublineage JN.1 variant XEC and has shown efficacy against multiple variants in non-clinical studies. The launch follows a distribution agreement with CSL Seqirus for sales in Japan, marking a significant step in the company’s efforts to combat COVID-19.
The most recent analyst rating on (ARCT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.
Spark’s Take on ARCT Stock
According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.
Arcturus Therapeutics’ overall stock score reflects significant financial challenges, despite positive technical indicators and promising corporate developments. The financial performance is the most significant factor, highlighting ongoing risks. However, positive earnings call sentiment and recent corporate achievements provide a balanced outlook.
To see Spark’s full report on ARCT stock, click here.
More about Arcturus Therapeutics
Average Trading Volume: 583,665
Technical Sentiment Signal: Hold
Current Market Cap: $555.3M
Find detailed analytics on ARCT stock on TipRanks’ Stock Analysis page.